Literature DB >> 28667389

Unmonitored use of herbal medicine by patients with breast cancer: reframing expectations.

Noah Samuels1, Eran Ben-Arye2,3, Yair Maimon4, Raanan Berger5.   

Abstract

PURPOSE: To identify the unmonitored use of herbal medicine by female patients with breast cancer, examining the impact of an integrative physician (IP) consultation on this practice.
METHODS: The files of 269 female patients with breast cancer following an IP consultation were surveyed retrospectively for use of herbal medicine for cancer-related goals. Expectations from the IP consultation and adherence to the IP-guided treatments were examined as well.
RESULTS: Among the cohort, 111 (41.3%) reported using herbal medicine for cancer-related goals, unmonitored by their oncology healthcare professional. Factors predicting herbal medicine use were the adoption of dietary changes (odds ratio = 13.6, p < 0.001, CI 7.16-26.0) and the expectation that the IP consultation and treatments would address cancer-related goals (odds ratio = 3.29, p = 0.001, CI 1.64-6.6). Patients with metastatic disease were more likely to be using herbal medicine than non-users (34.5 vs. 22.8%; p = 0.088), as were those who had consulted with a complementary/alternative medicine practitioner (54.9 vs. 20.8%; p = 0.005). The IP advised 17 patients (15.3%) to stop taking specific herbal products due to safety-related concerns; and 10 patients to take dietary supplements for relief of specific symptoms. Herbal medicine users were less likely than non-users to adhere to the IP-recommended treatment program (34.7 vs. 48.3%; p = 0.037).
CONCLUSIONS: Unmonitored use of herbal medicine by patients with breast cancer is more frequent among those adopting dietary changes for cancer-related goals. Integrative physicians provide evidence-based guidance on the safe and effective use of herbal products, and reframe patient expectations from cancer-related goals to reducing symptoms and improving quality of life.

Entities:  

Keywords:  Breast cancer; Complementary/integrative medicine; Herbal medicine; Herb–drug interaction; Safety

Mesh:

Year:  2017        PMID: 28667389     DOI: 10.1007/s00432-017-2471-x

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  23 in total

1.  Assessing patient adherence to a complementary medicine treatment regimen in an integrative supportive care setting.

Authors:  Eran Ben-Arye; Dikla Kruger; Noah Samuels; Lital Keinan-Boker; Tamar Shalom; Elad Schiff
Journal:  Support Care Cancer       Date:  2014-03       Impact factor: 3.603

Review 2.  Counseling patients on cancer diets: a review of the literature and recommendations for clinical practice.

Authors:  Jutta Huebner; Sabine Marienfeld; Clare Abbenhardt; Cornelia Ulrich; Karsten Muenstedt; Oliver Micke; Ralph Muecke; Christian Loeser
Journal:  Anticancer Res       Date:  2014-01       Impact factor: 2.480

Review 3.  Drug interactions with phytotherapeutics in oncology.

Authors:  Walter Emil Haefeli; Alexandra Carls
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-01-06       Impact factor: 4.481

4.  Integrative medicine consultation service in a comprehensive cancer center: findings and outcomes.

Authors:  Moshe Frenkel; Lorenzo Cohen; Noemi Peterson; J Lynn Palmer; Kay Swint; Eduardo Bruera
Journal:  Integr Cancer Ther       Date:  2010-08-11       Impact factor: 3.279

5.  Anti-platelet effects of Curcuma oil in experimental models of myocardial ischemia-reperfusion and thrombosis.

Authors:  Prem Prakash; Ankita Misra; William R Surin; Manish Jain; Rabi S Bhatta; Raghvendra Pal; Kanwal Raj; Manoj K Barthwal; Madhu Dikshit
Journal:  Thromb Res       Date:  2010-12-08       Impact factor: 3.944

6.  Patient-physician communication regarding use of complementary therapies during cancer treatment.

Authors:  Cleora S Roberts; Frank Baker; Danette Hann; Joan Runfola; Cathy Witt; Jamie McDonald; Mary L Livingston; Jane Ruiterman; Rosemarie Ampela; Okrae C K Kaw; Chris Blanchard
Journal:  J Psychosoc Oncol       Date:  2005

7.  Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.

Authors:  Sang-Chul Shin; Jun-Shik Choi
Journal:  Anticancer Drugs       Date:  2009-08       Impact factor: 2.248

8.  Unconventional medicine in the United States. Prevalence, costs, and patterns of use.

Authors:  D M Eisenberg; R C Kessler; C Foster; F E Norlock; D R Calkins; T L Delbanco
Journal:  N Engl J Med       Date:  1993-01-28       Impact factor: 91.245

9.  Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005.

Authors:  Heather S Boon; Folashade Olatunde; Suzanna M Zick
Journal:  BMC Womens Health       Date:  2007-03-30       Impact factor: 2.809

Review 10.  Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy.

Authors:  Anna Maria Barbuti; Zhe-Sheng Chen
Journal:  Cancers (Basel)       Date:  2015-12-03       Impact factor: 6.639

View more
  9 in total

1.  News from the European Association for Cancer Education: a Long-standing Partner of AACE.

Authors:  Sabine Fromm-Haidenberger
Journal:  J Cancer Educ       Date:  2018-12       Impact factor: 2.037

2.  Refugees in Conflict: Creating a Bridge Between Traditional and Conventional Health Belief Models.

Authors:  Eran Ben-Arye; Massimo Bonucci; Michel Daher; Rejin Kebudi; Bashar Saad; Thomas Breitkreuz; Maryam Rassouli; Elio Rossi; Nahla Gafer; Omar Nimri; Mohamed Hablas; Gunver Sophia Kienle; Noah Samuels; Michael Silbermann
Journal:  Oncologist       Date:  2017-12-28

3.  Trends in integrative medicine and health consults: differences between cancer survivors and patients without cancer.

Authors:  Noël M Arring; Denise Millstine; Debra L Barton; Karen S Lyons; Marlene Girardo; Amy Hutson; Lillian M Nail
Journal:  Support Care Cancer       Date:  2020-10-14       Impact factor: 3.603

4.  Integrative cancer care: crossing communication barriers.

Authors:  Eran Ben-Arye; Noah Samuels
Journal:  Oncotarget       Date:  2017-10-19

5.  The Cytochrome P450-Mediated Metabolism Alternation of Four Effective Lignans From Schisandra chinensis in Carbon Tetrachloride-Intoxicated Rats and Patients With Advanced Hepatocellular Carcinoma.

Authors:  Rongrong Wu; Zhiyong Xiao; Xiaorui Zhang; Feng Liu; Wenxia Zhou; Yongxiang Zhang
Journal:  Front Pharmacol       Date:  2018-03-14       Impact factor: 5.810

Review 6.  Exploring Herbal Medicine Use during Palliative Cancer Care: The Integrative Physician as a Facilitator of Pharmacist-Patient-Oncologist Communication.

Authors:  Noah Samuels; Eran Ben-Arye
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-11

7.  Use of Herbal Medicine Is Associated With Late-Stage Presentation in Tanzanian Patients With Cancer: A Survey to Assess the Utilization of and Reasons for the Use of Herbal Medicine.

Authors:  Oliver Henke; Walter Bruchhausen; Anna Massawe
Journal:  JCO Glob Oncol       Date:  2022-07

8.  Understanding CAM Use in Lebanon: Findings from a National Survey.

Authors:  Samer Kharroubi; Rana F Chehab; Chirine El-Baba; Mohamad Alameddine; Farah Naja
Journal:  Evid Based Complement Alternat Med       Date:  2018-07-25       Impact factor: 2.629

9.  Simultaneous Determination of Schisandrin and Promethazine with Its Metabolite in Rat Plasma by HPLC-MS/MS and Its Application to a Pharmacokinetic Study.

Authors:  Sijia Gao; Xuelin Zhou; Liwei Lang; Honghong Liu; Jianyu Li; Haotian Li; Shizhang Wei; Dan Wang; Zhuo Xu; Huadan Cai; Yanling Zhao; Wenjun Zou
Journal:  Int J Anal Chem       Date:  2019-12-09       Impact factor: 1.885

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.